RPS6KB1 and colorectal carcinoma: Additionally, we provide a comprehensive analysis of vertical inhibition of PI3Kα, AKT, and ribosomal protein S6 kinase (S6K) using FDA-approved drugs, including alpelisib and capivasertib, in combination with LY2584702, in CRC cell lines and 3D patient-derived organoids (PDOs).